• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Science & Medicine / Pharmaceuticals / Dispute over pneumococcal vaccine initiative

Dispute over pneumococcal vaccine initiative

February 3, 2011 By Jonathan 1 Comment


The Lancet, Volume 374, Issue 9705, Pages 1879 – 1880, 5 December 2009
doi:10.1016/S0140-6736(09)62078-X
The Global Alliance for Vaccines and Immunisation is at loggerheads with experts critical of the financing mechanism that it administers for pneumococcal vaccines. Ann Danaiya Usher reports.
The US$1·5 billion Advance Market Commitment (AMC) for pneumococcal vaccines was officially launched in June, 2009, at the G8 Summit in L’Aquila, Italy. With funding provided by Italy, the UK, Canada, Russia, Norway, and the Bill & Melinda Gates Foundation , the idea of the AMC is that it creates a market for vaccines that target developing country diseases by putting up a large subsidy and fixing the price at which vaccines are to be sold. But finding the right price has been a key stumbling block for the donors since the scheme was proposed by Italy in 2005.
Today the AMC is close to being realised with four companies expressing interest in supplying vaccine through the initiative. But unanswered questions remain about what this innovative funding mechanism will really cost and what it will achieve.
The initiative that was presented in L’Aquila sets the price per dose to be paid to participating firms at $7 per dose. 18 months earlier, donors were considering a much higher price.
An expert group headed by Ruth Levine, a senior fellow at the Center for Global Development—a think-tank based in Washington, DC, USA—had studied the options, and held consultations with vaccine producers to get a sense of their pain threshold. Days prior to what was meant to be the last meeting of the AMC donors (May, 2008) to hammer out the final details of the scheme, Levine’s group presented a report to the donors in which they recommended a price of $10 per dose.
Norway, alone among the donors, argued that this was too high and feared that the terms were being set “on industry’s premises”. Internal documents show that Norway insisted that the price should not be higher than $7, and managed to convince the other donors to agree.
The Global Alliance for Vaccines and Immunisation (GAVI) says that the initiative will save 7 million lives by 2030. A logical question is what was gained by pushing the price down by 30%? How many more lives are expected to be saved with this AMC compared with the higher price of $10? The difficulty of finding clear answers to these questions indicates one of the fundamental problems of the years-long AMC process: the lack of transparency in the deliberations, which has hampered informed public debate about this huge aid-financed project.
Promoters of the AMC say that in terms of lives saved, nothing was gained. “If a higher AMC price had been chosen, the same number of lives would have been saved”, says Tania Cernuschi, AMC manager at GAVI.
Ruth Levine concurs. “The number of doses is independent of the AMC price—although I realise it does sound a little counter-intuitive”, she says.
The reason given is complicated. Through the scheme, companies commit to supply a certain number of doses over 10 years. In the initial phase, the price is $7 per dose, after which the firms continue to supply the vaccine at a tail price that cannot exceed $3·50. GAVI covers most of the tail price for the remaining 10 years with developing country governments contributing a small share. GAVI hopes that companies will offer a price below $3·50 and that donors will provide GAVI with additional funds to purchase the vaccines, so that they can immunise more children.
Read More…

Related

Filed Under: Pharmaceuticals, Vaccine Marketing, Vaccine Politics/People Tagged With: immunizations, pharmaceuticals, pneumococcal disease, Vaccine Adverse Reactions

Trackbacks

  1. Tweets that mention Dispute over pneumococcal vaccine initiative | SaneVax General Blog -- Topsy.com says:
    February 4, 2011 at 9:30 pm

    […] This post was mentioned on Twitter by SaneVax, SaneVax. SaneVax said: Dispute over pneumococcal vaccine initiative https://sanevax.org/blog/?p=1961 […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Naomi from Australia

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

cervarix effects

Cervarix Effects

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in